Penile Pre-Cancer: Incidence, Treatment, and Immune Factors

What is it about?

This study is about penile intraepithelial neoplasia (PeIN), a pre-cancerous condition primarily caused by high-risk human papillomavirus (hrHPV) infection. It discusses the increasing incidence of PeIN in Europe and the role of HPV in its aetiology, with HPV-16 being the most common subtype. The study also covers clinical presentation, classification, and treatment options, focusing on imiquimod (IQ) as a first-line topical treatment. It mentions the need for further research on the PeIN immune microenvironment and potential predictive biomarkers for treatment response. The review suggests a treatment schedule of three times a week for 8-16 weeks with IQ, noting good response rates but potential side effects and recurrence risks. Lastly, it emphasizes the importance of histology in diagnosing PeIN to ensure appropriate treatment.

Featured Image

Why is it important?

This research is significant because it provides a comprehensive review of penile intraepithelial neoplasia (PeIN), a precancerous condition primarily caused by human papillomavirus (HPV) infection. Understanding PeIN is crucial for early detection and prevention of penile cancer, a rare but potentially devastating malignancy. The study's focus on imiquimod treatment and immune microenvironment markers offers potential for improving treatment outcomes and developing predictive biomarkers. This research contributes to the growing body of knowledge on HPV-related pre-malignancies and highlights the need for further investigation into effective treatment strategies and personalized medicine approaches in managing PeIN. Key Takeaways: 1. Incidence and Classification: The incidence of PeIN appears to be rising in Europe, with the updated WHO 2022 classification dividing PeIN into two categories based on hrHPV status, emphasizing the importance of early detection and appropriate classification for treatment planning. 2. Treatment Efficacy: Topical imiquimod treatment shows promise as a first-line option for PeIN, with complete response rates of up to 63%, though side effects and recurrence rates remain significant concerns, highlighting the need for optimized treatment protocols. 3. Immune Microenvironment: While data on the PeIN immune microenvironment is limited, studies on related conditions suggest that specific immune cell subpopulations may serve as predictors for successful immunomodulation treatments, pointing to the potential for developing personalized treatment approaches in the future.